Boston Scientific Buying Vessix, Providing an Exit for Multiple VCs
November 9, 2012- Share:
Boston Scientific (NYSE: BSX) is acquiring venture-funded Vessix Vascular, maker of a catheter-based device to treat uncontrolled hypertension. The purchase price includes an upfront payment of $125 million, with milestone payments of up to $400 million. Vessix snagged its final financing in August 2011, landing $23 million of Series B funding from Edmond de Rothschild Investment Partners, OrbiMed Advisors, CDF Dinova Venture Partners, NeoMed Management, Christopher Weil & Company and Fjord Ventures.
- Share:
-
-
-
-